CNTX
Context Therapeutics
$0.62
+$0.01 (+1.3%)Jul 27, 2026
Key metrics
The numbers that frame CNTX today
- Market cap
- $57.15M
- P/E (TTM)
- -1.4
- EV / FCF
- -0.1
- ROIC
- 1,376.9%
- Div yield
- 0%
- Debt / equity
- 0.0
- 52wk Low
- $0.55
- 52wk High
- $3.62
Growth
Revenue and earnings trend for CNTX
RevenueNet income
See the full growth breakdown
Revenue and earnings trends, margins and the multi-year trajectory - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inCash flow & returns
Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture
Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inInsider trading
Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade
See who is buying and selling, how much, and when - updated as new filings land.
Create a free accountFree foreverNo card required
Already a member? Log inFrequently asked questions
Plain-English answers about CNTX
Is Context Therapeutics a good buy?
No. Context Therapeutics has poor quality and poor momentum. Both signals point to a weaker setup. Growth looks excellent, which supports the long-term business case, but that is not enough to offset the weak setup. We think Context Therapeutics is selling at a very high price.
What is the market capitalization of CNTX?
Context Therapeutics's market capitalization is $57.15M.
What is the P/E ratio for CNTX stock?
Context Therapeutics's current P/E ratio is -1.4.
What is the 52-week high for CNTX stock?
The 52-week high for Context Therapeutics is $3.62. The current close of $0.62 is 82.8% below that high.
What is the 52-week low for CNTX stock?
The 52-week low for Context Therapeutics is $0.55. The current close of $0.62 is 14.1% above that low.
Does CNTX stock pay dividends?
Context Therapeutics does not currently show a dividend per share in the company data.
What is the Debt / Equity ratio for CNTX?
Context Therapeutics's Debt / Equity ratio is 0.01.